Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

Philip Raskin, Alok Mohan

Research output: Contribution to journalComment/debatepeer-review

8 Scopus citations

Abstract

The safety and efficacy of exenatide once weekly is evaluated over 52 weeks in the DURATION-1 trial in patients with type 2 diabetes. This long-acting glucagon-like peptide 1 receptor agonist given as a once weekly subcutaneous injection was found to produce better glycemic control as compared to twice daily exenatide and had a good safety profile over the trial period. Its use can help to reduce the complexity of drug regimen in patients with type 2 diabetes while maintaining a good safety and efficacy profile.

Original languageEnglish (US)
Pages (from-to)2269-2271
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number13
DOIs
StatePublished - Sep 1 2010

Keywords

  • DURATION-1 trial
  • Exenatide
  • GLP-1 receptor agonist
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)'. Together they form a unique fingerprint.

Cite this